title: The expression of annexin II and its role in the fibrinolytic activity in acute promyelocytic leukemia.
abstract: Bleeding in acute promyelocytic leukemia (APL) is mainly associated with disseminated intravascular coagulation and hyperfibrinolysis. Annexin II (Ann II) is a co-receptor for plasminogen and tissue plasminogen activator (tPA). This study demonstrates that abnormally high levels of Ann II expression in APL cells increase the production of plasmin. Hyperfibrinolysis could be corrected by all-trans retinoic acid (ATRA) or ATRA plus arsenic trioxide therapy in patients with APL. SiRNA targetting Ann II caused a decrease in tPA-dependent plasmin generation, while Ann II cDNA transfectant stimulated plasmin production. These results suggest that Ann II play an important role in hyperfibrinolysis in APL.
authors.affiliation: Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, 188 Shizi Street, Suzhou, Jiangsu Province 215006, China.
authors.forename: Yanhui
authors.initials: Y
authors.lastname: Liu
authors.forename: Zhaoyue
authors.initials: Z
authors.lastname: Wang
authors.forename: Miao
authors.initials: M
authors.lastname: Jiang
authors.forename: Lan
authors.initials: L
authors.lastname: Dai
authors.forename: Wei
authors.initials: W
authors.lastname: Zhang
authors.forename: Depei
authors.initials: D
authors.lastname: Wu
authors.forename: Changgeng
authors.initials: C
authors.lastname: Ruan
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D017306:Annexin A2 / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000008:administration & dosage; D001780:Blood Coagulation Tests; D015153:Blotting, Western; D049109:Cell Proliferation / Q000187:drug effects; D005260:Female; D005341:Fibrinolysin / Q000378:metabolism; D005342:Fibrinolysis / Q000187:drug effects / Q000502:physiology*; D005434:Flow Cytometry; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010087:Oxides / Q000008:administration & dosage; D010958:Plasminogen / Q000378:metabolism; D012333:RNA, Messenger / Q000235:genetics; D034741:RNA, Small Interfering / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D010959:Tissue Plasminogen Activator / Q000378:metabolism; D014212:Tretinoin / Q000008:administration & dosage; D055815:Young Adult
chemical_list: D017306:Annexin A2; D001152:Arsenicals; D010087:Oxides; D012333:RNA, Messenger; D034741:RNA, Small Interfering; D014212:Tretinoin; D010958:Plasminogen; D010959:Tissue Plasminogen Activator; D005341:Fibrinolysin; D000077237:Arsenic Trioxide